Bionomics will recruit about 40 elderly patients in specialist geriatric hospital wards across Australia.
Showing 25 of 1015
The company's shares are trading about 9% higher intra-day, at 4.9 cents.
Earlier this month the company raised $6 million through a share placement.
The 3D valve recently passed a critical viability test, successfully completing more than 200 million simulated cycles.
The company is focused on developing a range of cannabinoid-based medical treatments.
Home monitoring using modern wearables and mobile products is a growth industry.
The company’s proprietary platform, BARD1, is based on novel tumour markers with potential diagnostic applications.
The company recently raised $6 million to expand and progress its strategic projects.
The results readout for the study is expected during the December quarter this year.
Coverage of the company’s ColoSTAT™ antibody-based blood test has been confirmed in 13 countries.
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
The sublingual cannabis wafer is a unique combination of Bod’s proprietary ECs315 cannabis extract and iX Biopharma’s ‘WaferiX’ technology.
The placement to institutional and sophisticated investors will be followed by a share purchase plan for existing shareholders.
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
The company has plans to grow medicinal cannabis on land leased in northern New South Wales.
The new agreements have synergies with the recent biomanufacturing facility acquisition.
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.
Bringing a unique and differentiated product range to the world's fastest-growing market.
Oswell's background in product development is expected to benefit Admedus' portfolio of development projects.
The opening order worth $1.1 million will be supplied between June and December 2018.
Large pharma companies are being attracted to the company’s drug development portfolio.
March quarter revenue was 31% higher than the previous quarter and extrapolates to annual revenue of $4.3 million.
The terms of the agreement are based on a minimum initial investment of $18 million for a 60% interest in Admedus Vaccines.
Notably, receipts from customers for the March quarter were up 31% to $1.079 million.
évolis® Professional is an anti-ageing hair care product range.